William Blair Brokers Boost Earnings Estimates for SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – William Blair increased their Q4 2024 earnings per share estimates for ARS Pharmaceuticals in a research note issued on Tuesday, January 21st. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of $0.28 for the quarter, up from their prior forecast of $0.26. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.58) per share.

Several other equities analysts have also recently issued reports on SPRY. Raymond James boosted their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Leerink Partners increased their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $26.00.

ARS Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ SPRY opened at $13.55 on Wednesday. The firm has a fifty day simple moving average of $12.46 and a two-hundred day simple moving average of $12.93. ARS Pharmaceuticals has a 12 month low of $6.13 and a 12 month high of $18.51. The firm has a market capitalization of $1.32 billion, a PE ratio of -26.57 and a beta of 0.96.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several large investors have recently modified their holdings of SPRY. Rhumbline Advisers increased its stake in ARS Pharmaceuticals by 78.0% during the 2nd quarter. Rhumbline Advisers now owns 65,942 shares of the company’s stock valued at $561,000 after purchasing an additional 28,888 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of ARS Pharmaceuticals by 20.7% during the second quarter. American Century Companies Inc. now owns 97,803 shares of the company’s stock valued at $832,000 after buying an additional 16,761 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of ARS Pharmaceuticals by 884.9% during the second quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock valued at $1,056,000 after acquiring an additional 111,500 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in ARS Pharmaceuticals in the 2nd quarter worth approximately $180,000. Finally, Creative Planning raised its holdings in ARS Pharmaceuticals by 7.0% in the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after acquiring an additional 2,307 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the completion of the transaction, the insider now owns 5,274,735 shares in the company, valued at approximately $95,156,219.40. The trade was a 9.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Laura Shawver sold 14,772 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $13.75, for a total value of $203,115.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,892,257.50. This represents a 6.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,095,558 shares of company stock worth $16,853,686. 40.10% of the stock is currently owned by company insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.